Market Update: Top Analysts Comment On Avalanche, Whole Foods And Twitter

Chardan analyst Gbola Amusa said the bad news about Avalanche Biotechnologies Inc AAVL is that his firm has no choice but to interpret that its CEO’s unexpected resignation is an indication that Phase IIa data for AVA-101 fell short of expectations, a conclusion that supports Chardan’s fears that Avalanche’s gene therapy approach to Ophthalmology is flawed.

The stock was down nearly 4 percent in Monday’s intra-day trading.

Oppenheimer analyst Rupesh Parikh commented on Whole Foods Market, Inc. WFM, noting that the company is likely to report “another sluggish quarter” but shares are still “appropriate” for long-term investors.

Shares were down 0.72 percent on Monday.

SunTrust's Bob Peck noted that Twitter Inc TWTR's earnings report on Tuesday will show a “tough” quarter with little to no growth in core monthly active users. He expects Q2 core MAU at flat 302 million.

The stock was down 3 percent.